Research

Hormonal

Subcutaneous Tirzepatide significantly reduces body weight, BMI, and waist circumference in adults with obesity or type 2 diabetes compared to placebo.

If you have obesity or type 2 diabetes and lifestyle changes haven't been enough, Tirzepatide is a highly effective, once-weekly injection that significantly reduces weight, BMI, and waist circumference. The effect is dose-dependent, with higher doses (up to 15mg) yielding greater weight loss. Be prepared for potential gastrointestinal side effects like nausea, which are common but often manageable.

GoodSupportsHIGH confidence
The pooled findings showed that Tirzepatide vs placebo significantly reduced body weight (weighted mean difference (WMD): -11.34 kg, 95% confidence interval (CI): -12.79 to -9.88, P< 0.001), body mass index (BMI) (WMD: -3.11 kg/m2, 95% CI: -4.36 to -1.86, P< 0.001), and waist circumference (WC) (WMD: -7.24 cm 95% CI -10.12 to -4.36, P< 0.001).
Pejman Rohani et al. · Frontiers in Endocrinology · 2023

Why this rating

High-quality systematic review and meta-analysis of 8 RCTs with 7062 participants, though heterogeneity was high.

Source

The effects of subcutaneous Tirzepatide on obesity and overweight: a systematic review and meta‐regression analysis of randomized controlled trials

Pejman Rohani et al. · Frontiers in Endocrinology · 2023

DOI 10.3389/fendo.2023.1230206

Meta-analysis · 8 studiesCited 17×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →